Press Releases

Calistoga Pharmaceuticals is pleased to have been selected to Fierce Biotech's Fierce 15 for 2009

1 July 2009 | FierceBiotech |

Calistoga Pharmaceuticals Reports Additional Clinical Responses in Ongoing Clinical Trial of CAL-101, an Isoform-Selective PI3 Kinase Inhibitor, Under Evaluation in Patients with Hematologic Malignancies

6 June 2009 | PDF |

Calistoga Pharmaceuticals' CAL-101, an Oral Delta Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Clinical Activity in Patients with Hematologic Cancers

30 May 2009 | PDF |

Calistoga Pharmaceuticals Raises $30 Million in Series B Financing

5 May 2009 | PDF |

Calistoga Pharmaceuticals Announces Presentations on CAL-101 and CAL-120 at the American Association for Cancer Research Annual Meeting

21 April 2009 | PDF |

Calistoga Pharmaceuticals Announces Appointment of Clifford J. Stocks as Chief Business Officer

11 March 2009 | PDF |

CAL-101, an Oral p110δ (delta) Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Preclinical Activity in Hematologic Cancer Cells

8 December 2008 | PDF |

Calistoga Pharmaceuticals appoints Carol G. Gallagher, Pharm. D., Chief Executive Officer

8 October 2008 | PDF |

Calistoga Pharmaceuticals Initiates First Oncology Clinical Trial Of Novel PI3K Delta Inhibitor, CAL-101

10 July 2008 | PDF |

Calistoga Pharmaceuticals initiates its First Clinical Study of Novel Oral PI3K Delta Compound, CAL-101.

10 March 2008 | PDF |

Reuters – New target promises better asthma and allergy drugs.

14 February 2008 |  |

Calistoga Pharmaceuticals Appoints R. Lee Douglas to BOD

13 February 2008 | PDF |

Calistoga Pharmaceuticals announces completion of its Series A Financing – Investors increased funding by 25% to total $26.2 Million

3 January 2008 | PDF |

Calistoga Pharmaceuticals, a newly formed drug development company, announces its formation and completion of $21 million Series A Financing

5 March 2007 | PDF |